CoChat

Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis

Rizos, Evangelos C, Markozannes, Georgios, Tsapas, Apostolos, Mantzoros, Christos S, Ntzani, Evangelia E · 2021 · Heart
Cited by 39

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: Omega-3 supplements are popular for cardiovascular disease (CVD) prevention. We aimed to assess the association between dose-specific omega-3 supplementation and CVD outcomes. Design: We included double-blind randomised clinical trials with duration ≥1 year assessing omega-3 supplementation and estimated the relative risk (RR) for all-cause mortality, cardiac death, sudden death, myocardial infarction and stroke. Primary analysis was a stratified random-effects meta-analysis by omega-3 dose in 4 a priori defined categories (<1, 1, 2, ≥3 of 1 g capsules/day). Complementary approaches were trial sequential analysis and sensitivity analyses for triglycerides, prevention setting, intention-to-treat analysis, eicosapentaenoic acid, sample size, statin use, study duration. Results: Seventeen studies (n=83 617) were included. Omega-3 supplementation as ≤1 capsule/day was not associated with any outcome under study; futility boundaries were crossed for all-cause mortality and cardiac death. For two capsules/day, we observed a statistically significant reduction of cardiac death (n=3, RR 0.55, 95% CI 0.33 to 0.90, I 2=0%); for ≥3 capsules/day we observed a statistically significant reduction of cardiac death (n=3, RR 0.82, 95% CI 0.68 to 0.99, I 2=0%), sudden death (n=1, RR 0.70, 95% CI 0.51 to 0.97) and stroke (n=2, RR 0.74, 95% CI 0.57 to 0.95, I 2=0%). Conclusion: Omega-3 supplementation at <2 1 g capsules/day showed no association with CVD outcomes; this seems unlikely to change from future research. Compared with the robust scientific evidence available for low doses, the evidence for higher doses (2–4 1 g capsules/day) is weak. The emerging postulated benefit from high-dose supplementation needs replication and further evaluation as to the precise formulation and indication.

Overview

Integrity signals

Registry

Crossref · 10.1136/heartjnl-2020-316780

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 12

  1. 10.1001/2012.jama.11374 · DOI · Paper page
  2. Aung, 2018, Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals, JAMA Cardiol, 3, 225, 10.1001/jamacardio.2017.5205 · DOI · Paper page
  3. 10.1016/j.jacc.2012.11.021 · DOI
  4. 10.1097/HJR.0b013e328339cc70 · DOI · Paper page
  5. 10.1159/000207441 · DOI · Paper page
  6. Nilsen, 2001, Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol, Am J Clin Nutr, 74, 50, 10.1093/ajcn/74.1.50 · DOI · Paper page
  7. 10.7326/0003-4819-130-7-199904060-00003 · DOI · Paper page
  8. 10.1016/S0261-5614(98)80318-X · DOI
  9. 10.1016/0735-1097(95)00095-L · DOI · Paper page
  10. 10.1023/A:1007757724505 · DOI · Paper page
  11. Qato, 2016, Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011, JAMA Intern Med, 176, 473, 10.1001/jamainternmed.2015.8581 · DOI · Paper page
  12. 10.1161/JAHA.113.000506 · DOI · Paper page

Cited by

See all 39

Metadata

Authors
Rizos, E. C., Markozannes, G., Tsapas, A., Mantzoros, C. S., & Ntzani, E. E.
Venue
Heart
Publisher
BMJ
Published
2020-08-20
Volume
107
Issue
2
Pages
150-158
ISSN
  • 1355-6037
  • 1468-201X
Cited by
39
References
16
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. https://app.cochat.ai/papers/10.1136/heartjnl-2020-316780
The paper
Rizos, E. C., Markozannes, G., Tsapas, A., Mantzoros, C. S., & Ntzani, E. E. (2021). Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. Heart. https://doi.org/10.1136/heartjnl-2020-316780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.